CRISPR gene-editing used on antibody-making B cells
May 17, 2019
| By Sabin Russell / Fred Hutch News Service
A Hutch team led by Dr. Justin Taylor shows that B cells, which are crucial components of the immune system, can be genetically engineered to make exactly the antibodies we want. It could lead to a potentially more precise and dependable way to generate protection without vaccines.
Led by NIH, Fred Hutch researchers, early study holds promise for direct infusion or vaccine design
March 19, 2018
| By Mary Engel / Fred Hutch News Service
Fred Hutch structural biologist Dr. Marie Pancera is seeking clues for designing a malaria vaccine by studying the differences between newly discovered antibodies that bind the same site on the malaria parasite.
New research writes latest chapter in one drug's story
June 27, 2017
| by Susan Keown / Fred Hutch News Service
The leukemia drug gemtuzumab ozogamicin (Mylotarg) was pulled from the market seven years after initial approval. Now, new evidence may be bringing it back to life to treat a specific group of patients.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.